GlycoMimetics has raised $15.4 million in its second round of venture capital. New Enterprise Associates led the round. Gaithersburg, MD-based GMI is developing novel drug therapies based on specific roles played by certain carbohydrates. Its lead drug candidates--an anti-inflammatory and an anti-infective--are in preclinical development.
- here's the release on GMI's round